Clinical Trials Logo
  1. Home
  2. Chronic Cough
  3. NCT04525885

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

Chronic Cough Clinical Trial

Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)

Clinical Trial Summary

The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.

Clinical Trial Description

This study will have a main 24-week treatment period and a 28-week extension period of treatment. Participants at selected sites and countries who complete the main and extension study periods may consent to participate in an observational, 3-month, Off-treatment Durability Study Period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04525885
Study type Interventional
Source Merck Sharp & Dohme LLC
Contact
Status Completed
Phase Phase 3
Start date May 17, 2019
Completion date September 15, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT01432730 - A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) Phase 2
Not yet recruiting NCT01413698 - Cough Count Validation N/A
Completed NCT03639727 - Cough in Eastern and Central Finland N/A
Completed NCT03696108 - A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) Phase 3
Recruiting NCT03638063 - ATP and Capsaicin Cough Provocation Test in Chronic Cough and Bronchiectasis
Completed NCT03172130 - Sham CPAP vs. Straight CPAP for Chronic Cough N/A
Recruiting NCT06286163 - Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients
Completed NCT03622216 - A Dose Escalation Study of Bradanicline in Refractory Chronic Cough Phase 2
Recruiting NCT05522699 - Cough Suppressive Therapy in Patients With Chronic Cough N/A
Completed NCT01297790 - Cough Responses to Tussive Agents in Health and Disease N/A
Completed NCT04193202 - Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043) Phase 3
Completed NCT01865422 - French Linguistic and Metric Validations of Parent-proxy QOL Chronic Cough Specific Questionnaire (PC-QOL) N/A
Completed NCT04193176 - Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) Phase 3
Recruiting NCT05362097 - Analysis of the Reliability and Validity of the Chinese Version of CC-QoL
Recruiting NCT03787511 - Chronic Cough and Small Fiber Neuropathy N/A
Terminated NCT03864328 - A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF Phase 2
Completed NCT05274516 - A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration Phase 1
Not yet recruiting NCT01807832 - The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough. N/A
Enrolling by invitation NCT05689307 - Validation Study With a Non-CE Marked Medical Device (MD) N/A
Completed NCT03482713 - Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033) Phase 2